Short answer
Monopar Therapeutics (MNPR) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 7.01 (Regulation FD Disclosure). Susan Rodriguez appointed Chief Commercial and Strategy Officer at Monopar Therapeutics, effective March 2, 2026.
Monopar Therapeutics 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Susan Rodriguez appointed Chief Commercial and Strategy Officer at Monopar Therapeutics, effective March 2, 2026
- New C-suite role signals commercial buildout phase: typically precedes or accompanies product launch preparations
- No compensation terms or equity grants disclosed in this filing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monopar Therapeutics 8-K filings
Get the next MNPR 8-K as it lands
Follow MNPR for push alerts, or ask the research agent what this filing means.